Orthobiologic Products Must Become Procedure-Specific

Editor’s Note: Orthobiologics play a role in every orthopedic market segment; therefore, the importance of their advancements affects the industry as a whole. We asked Andy Carter, Ph.D., Chief Technology Officer at TheraCell, to give his insight on the orthobiologics market—as it stands now, and where it’s heading in the near future. His...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Andy Carter an executive with over 30 years of medical device experience, primarily in orthopedics, biomaterials and tissue engineering. Dr. Carter has worked both in large corporations, startups and small companies and has managed both research and development programs.

Contact Us